Skip to content

Pharminent

cropped-banner_frontpage_2026-07-11-2.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Commercial
  • Approvals in Hand, Lilly and Novo Obesity Pills Will Battle It Out on Hairline Differences
  • Commercial

Approvals in Hand, Lilly and Novo Obesity Pills Will Battle It Out on Hairline Differences

BioSpace

After Eli Lilly achieved the milestone approval of the weight loss pill Foundayo, Novo Nordisk launched a full-court press to defend oral Wegovy, which has been enjoying a record-breaking launch since

CommercialMetabolic & GLP-1Read full story

pharminent April 2, 2026 (Last updated: April 2, 2026)

BioSpace

After Eli Lilly achieved the milestone approval of the weight loss pill Foundayo, Novo Nordisk launched a full-court press to defend oral Wegovy, which has been enjoying a record-breaking launch since

CommercialMetabolic & GLP-1Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Rare Disease Leaders Call for Regulatory Clarity as FDA Balances Urgency With Rigor
Next: Pharma’s M&A Train Is on Track for Record Highs With More Deals To Come: Analysts

Related Stories

  • Commercial

Wegovy pill launches in UK as first daily oral GLP1 for weight management

pharminent July 6, 2026
  • Commercial

Tryngolza charts blockbuster course after FDA’s hypertriglyceridemia approval

pharminent June 26, 2026
  • Commercial

Lilly launches its LillyDirect sales channel in the UK

pharminent June 25, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.